Trevi Therapeutics, Inc.
NASDAQ:TRVI
4 (USD) • At close December 24, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.123 | 0.043 | 0.05 | 0.047 | 0.039 | 0.023 | 0 | 0.004 |
| Gross Profit
| -0.123 | -0.043 | -0.05 | -0.047 | -0.039 | -0.023 | 0 | -0.004 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 23.683 | 19.834 | 22.984 | 22.328 | 19.339 | 14.072 | 6.095 | 6.913 |
| General & Administrative Expenses
| 9.953 | 10.073 | 9.492 | 10.161 | 7.306 | 4.336 | 2.142 | 1.658 |
| Selling & Marketing Expenses
| 0.287 | 0 | 0 | 0 | 0 | 0 | 0 | 0.05 |
| SG&A
| 10.24 | 10.073 | 9.492 | 10.161 | 7.306 | 4.336 | 2.142 | 1.708 |
| Other Expenses
| 0 | 0.719 | -0.375 | -0.287 | 0.577 | -2.243 | -0.024 | 0 |
| Operating Expenses
| 33.923 | 29.907 | 32.476 | 32.489 | 26.645 | 18.408 | 8.237 | 8.621 |
| Operating Income
| -33.923 | -29.907 | -32.476 | -32.489 | -26.645 | -18.408 | -8.237 | -8.625 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 4.826 | 0.719 | -1.485 | -0.287 | 0.577 | -2.261 | -4.649 | -2.47 |
| Income Before Tax
| -29.097 | -29.188 | -33.961 | -32.776 | -26.068 | -20.669 | -12.886 | -11.095 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.032 | -0.036 | -0.021 | -0.018 | -0.018 | -0.124 | -0.026 | -0.008 |
| Net Income
| -29.065 | -29.152 | -33.94 | -32.758 | -26.05 | -20.545 | -12.86 | -11.087 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.29 | -0.45 | -1.49 | -1.81 | -2.22 | -2.29 | -1.43 | -0.69 |
| EPS Diluted
| -0.29 | -0.45 | -1.49 | -1.81 | -2.22 | -2.29 | -1.43 | -0.69 |
| EBITDA
| -33.8 | -29.864 | -32.426 | -32.442 | -26.606 | -18.385 | -8.188 | -8.621 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |